EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Breast metastases from non-primary breast malignancies: What should we know?

Ángela Santana Valenciano, Luz Divina Juez Sáez, Belén Pérez Mies, Sara Corral Moreno, Sonia Rivas Fidalgo, Jacobo Cabañas Montero

Breast Disease · 2023

DOI: 10.3233/bd-220056 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Disease, 2023. Verfasst von Ángela Santana Valenciano und 5 weiteren Autor:innen. Beteiligte Einrichtung: General and Digestive Surgery Department, University Hospital Ramón y Cajal, Madrid, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Metastases from extramammary malignant neoplasms are very rare, accounting for less than 2% of all breast malignancies. OBJECTIVE: The aim of this study is to describe the clinicopathological features and prognosis of breast metastases from non-primary breast malignancies at our institution. METHODS: We performed a retrospective observational study, obtaining data from electronic medical records and pathology databases between January 1985 and December 2020 for patients diagnosed with breast metastasis from non-primary breast malignancies. Only patients diagnosed by biopsy were included. RESULTS: Fifteen patients diagnosed with breast metastases from non-primary breast malignancies were included, 13 women (86,67%) and 2 men (13,33%). The median age at time of initial diagnosis was 56 years (IQR 21–68). The most frequent primary malignancy was melanoma (9/15; 60%). The median time to diagnosis of breast metastases was 65 months (IQR 13–106). The most common diagnostic modality was CT-scan (10/15; 66,67%). The median follow-up was 96 months (IQR 29–136). Eight patients underwent surgery (53,3%), being the most common surgical intervention breast-conserving surgery (5/8; 62,5%). Mortality at the end of follow-up was 53,3% (8/15). On the survival analysis, we found no differences between patients undergoing surgery and those only receiving systemic treatment [41,5 months (IQR 17,5–57,5) versus 14 months (IQR 2–24), respectively; p = 0,161]. CONCLUSIONS: Breast metastases from non-primary breast malignancies are extremely rare and represent a diagnostic and therapeutic challenge, due to the poor prognosis of these patients. Thus, arriving at the correct diagnosis is crucial to avoid unnecessary treatment in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedYoung AdultBreastMelanomaRetrospective StudiesSkin NeoplasmsAdolescentSurvival Analysis

Stichwörter der Autor:innen

Breast metastasesdiagnosisextramammary malignanciestreatment

Autor:innen und Institutionen

  • General and Digestive Surgery Department, University Hospital Ramón y Cajal, Madrid, Spain.
  • Pathology Department, University Hospital Ramón y Cajal, Madrid, Spain.

Zitieren

APA

Santana Valenciano, Á., Juez Sáez, L. D., Pérez Mies, B., Moreno, S. C., Fidalgo, S. R., & Montero, J. C. (2023). Breast metastases from non-primary breast malignancies: What should we know?. Breast Disease. https://doi.org/10.3233/bd-220056

Vancouver

Santana Valenciano Á, Juez Sáez LD, Pérez Mies B, Moreno SC, Fidalgo SR, Montero JC. Breast metastases from non-primary breast malignancies: What should we know?. Breast Disease. 2023. doi:10.3233/bd-220056

BibTeX
@article{SantanaValenciano2023,
  author = {Santana Valenciano, Ángela and Juez Sáez, Luz Divina and Pérez Mies, Belén and Moreno, Sara Corral and Fidalgo, Sonia Rivas and Montero, Jacobo Cabañas},
  title = {Breast metastases from non-primary breast malignancies: What should we know?},
  journal = {Breast Disease},
  year = {2023},
  doi = {10.3233/bd-220056}
}
Kostenlos starten →